Baidu
map

感染指南

订阅

MedSci主页 / 所有栏目 / 感染指南

2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理

2018-12-22 意大利风湿病学学会 Mod Rheumatol. 2018 Dec 22:1-23.

类风湿性关节炎丙型肝炎感染

直接抗病毒药物（DAAs）可清除丙肝病毒(HCV），使特殊情况的患者，例如风湿性关节炎患者HCV感染的管理得到极大改善。本文主要针对RA患者合并HCV感染的管理提出指导建议。

中文标题：

2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理

英文标题：

Italian Consensus Recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis.

发布机构：

意大利风湿病学学会

发布日期：

2018-12-22

简要介绍：

直接抗病毒药物（DAAs）可清除丙肝病毒(HCV），使特殊情况的患者，例如风湿性关节炎患者HCV感染的管理得到极大改善。本文主要针对RA患者合并HCV感染的管理提出指导建议。 

拓展指南：与类风湿性关节炎相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理)] GetToolGuiderByIdResponse(projectId=1, id=d67fd1c0016836cc, title=2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理, enTitle=Italian Consensus Recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis., guiderFrom=Mod Rheumatol. 2018 Dec 22:1-23., authorId=null, author=, summary=直接抗病毒药物（DAAs）可清除丙肝病毒(HCV），使特殊情况的患者，例如风湿性关节炎患者HCV感染的管理得到极大改善。本文主要针对RA患者合并HCV感染的管理提出指导建议。 , cover=, journalId=null, articlesId=null, associationId=1454, associationName=意大利风湿病学学会, associationIntro=, copyright=0, guiderPublishedTime=Sat Dec 22 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>直接抗病毒药物（DAAs）可清除丙肝病毒(HCV），使特殊情况的患者，例如风湿性关节炎患者HCV感染的管理得到极大改善。本文主要针对RA患者合并HCV感染的管理提出指导建议。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>类风湿性关节炎</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=c4c9e1c00165282c" title="2018 SFR建议：类风湿性关节炎的管理（更新）" target=_blank>2018 SFR建议：类风湿性关节炎的管理（更新）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=9542f1c001615e3f" title="2018 多学科建议：类风湿性关节炎患者足部问题的诊断和治疗" target=_blank>2018 多学科建议：类风湿性关节炎患者足部问题的诊断和治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=cd2cb1c0015a14d5" title="2017 EULAR建议：支持观察研究的核心数据集和类风湿性关节炎的临床护理" target=_blank>2017 EULAR建议：支持观察研究的核心数据集和类风湿性关节炎的临床护理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=057981c00151e549" title="《2017年意大利共识指南：类风湿性关节炎患者HBV感染的管理》摘译" target=_blank>《2017年意大利共识指南：类风湿性关节炎患者HBV感染的管理》摘译</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=18ccf1c001a41e99" title="2017 意大利共识指南：类风湿性关节炎患者丙肝病毒感染的管理" target=_blank>2017 意大利共识指南：类风湿性关节炎患者丙肝病毒感染的管理</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E7%B1%BB%E9%A3%8E%E6%B9%BF%E6%80%A7%E5%85%B3%E8%8A%82%E7%82%8E" target=_blank>有关类风湿性关节炎更多指南</a></ul>, tagList=[TagDto(tagId=2259, tagName=类风湿性关节炎), TagDto(tagId=37582, tagName=丙型肝炎感染)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8657, appHits=131, showAppHits=8, pcHits=6578, showPcHits=2624, likes=254, shares=3, comments=20, approvalStatus=1, publishedTime=Fri Jan 04 23:49:15 CST 2019, publishedTimeString=2018-12-22, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Jan 04 23:49:15 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 20:41:02 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理)])
2018 意大利共识建议：类风湿性关节炎丙型肝炎感染的管理
下载请点击：
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=357342, encodeId=7eb335e34299, content=学习了长知识学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:50:07 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357341, encodeId=c70e35e3411f, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:58 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357340, encodeId=274b35e34005, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:54 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357339, encodeId=25fa35e339e2, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:50 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357338, encodeId=aa9035e33839, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:47 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 Y—xianghai

    学习了长知识学习了新知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=357342, encodeId=7eb335e34299, content=学习了长知识学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:50:07 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357341, encodeId=c70e35e3411f, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:58 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357340, encodeId=274b35e34005, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:54 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357339, encodeId=25fa35e339e2, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:50 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357338, encodeId=aa9035e33839, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:47 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 Y—xianghai

    学习了新知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=357342, encodeId=7eb335e34299, content=学习了长知识学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:50:07 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357341, encodeId=c70e35e3411f, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:58 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357340, encodeId=274b35e34005, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:54 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357339, encodeId=25fa35e339e2, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:50 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357338, encodeId=aa9035e33839, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:47 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 Y—xianghai

    学习了长知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=357342, encodeId=7eb335e34299, content=学习了长知识学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:50:07 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357341, encodeId=c70e35e3411f, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:58 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357340, encodeId=274b35e34005, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:54 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357339, encodeId=25fa35e339e2, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:50 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357338, encodeId=aa9035e33839, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:47 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 Y—xianghai

    学习了新知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=357342, encodeId=7eb335e34299, content=学习了长知识学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:50:07 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357341, encodeId=c70e35e3411f, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:58 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357340, encodeId=274b35e34005, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:54 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357339, encodeId=25fa35e339e2, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:50 CST 2019, time=2019-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357338, encodeId=aa9035e33839, content=学习了长知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Sun Jan 06 10:49:47 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 Y—xianghai

    学习了长知识

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 SFR建议：类风湿性关节炎的管理（更新）

法国风湿病学学会(SFR,French Society for Rheumatology) · 2018-10-10

2018 多学科建议：类风湿性关节炎患者足部问题的诊断和治疗

国外风湿免疫科相关专家小组 · 2018-07-04

2017 EULAR建议：支持观察研究的核心数据集和类风湿性关节炎的临床护理

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2018-01-04

《2017年意大利共识指南：类风湿性关节炎患者HBV感染的管理》摘译

暂未更新 · 2017-11-05

2016 EULAR建议：应用合成的和生物类改善病情的抗风湿药物治疗类风湿性关节炎（更新版）

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2017-03-06

2016 NICE技术评估指南：Certolizumab pego用于治疗TNFα抑制剂治疗反应不敏感类风湿性关节炎（TA415）

暂未更新 · 2016-10-26

Baidu
map
Baidu
map
Baidu
map